-
Something wrong with this record ?
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
MV. Mateos, H. Nahi, W. Legiec, S. Grosicki, V. Vorobyev, I. Spicka, V. Hungria, S. Korenkova, N. Bahlis, M. Flogegard, J. Bladé, P. Moreau, M. Kaiser, S. Iida, J. Laubach, H. Magen, M. Cavo, C. Hulin, D. White, V. De Stefano, PL. Clemens, T....
Language English Country Great Britain
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
- MeSH
- Survival Analysis MeSH
- Adult MeSH
- Injections, Subcutaneous MeSH
- Administration, Intravenous MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Multiple Myeloma drug therapy MeSH
- Antibodies, Monoclonal administration & dosage adverse effects therapeutic use MeSH
- Antineoplastic Agents administration & dosage adverse effects therapeutic use MeSH
- Aged MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. METHODS: In this ongoing, multicentre (147 sites in 18 countries), open-label, non-inferiority, randomised, phase 3 trial, we recruited adult patients (age ≥18 years) if they had confirmed relapsed or refractory multiple myeloma according to International Myeloma Working Group criteria; received at least three previous lines of therapy, including a proteasome inhibitor and immunomodulatory drug, or were double refractory to both a proteasome inhibitor and immunomodulatory drug; and had an Eastern Cooperative Oncology Group performance status score of 2 or lower. Patients were randomly assigned (1:1) by a computer-generated randomisation schedule and balanced using randomly permuted blocks to receive daratumumab subcutaneously (subcutaneous group) or intravenously (intravenous group). Randomisation was stratified on the basis of baseline bodyweight (≤65 kg, 66-85 kg, >85 kg), previous therapy lines (≤four vs >four), and myeloma type (IgG vs non-IgG). Patients received 1800 mg of subcutaneous daratumumab co-formulated with 2000 U/mL recombinant human hyaluronidase PH20 or 16 mg/kg of intravenous daratumumab once weekly (cycles 1-2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter (28-day cycles) until progressive disease or toxicity. The co-primary endpoints were overall response and maximum trough concentration (Ctrough; cycle 3, day 1 pre-dose). The non-inferiority margin for overall response was defined using a 60% retention of the lower bound (20·8%) of the 95% CI of the SIRIUS trial. Efficacy analyses were done by intention-to-treat population. The pharmacokinetic-evaluable population included all patients who received all eight weekly daratumumab doses in cycles 1 and 2 and provided a pre-dose pharmacokinetics blood sample on day 1 of cycle 3. The safety population included all patients who received at least one daratumumab dose. This trial is registered with ClinicalTrials.gov, NCT03277105. FINDINGS: Between Oct 31, 2017, and Dec 27, 2018, 655 patients were screened, of whom 522 were recruited and randomly assigned (subcutaneous group n=263; intravenous group n=259). Three patients in the subcutaneous group and one in the intravenous group did not receive treatment and were not evaluable for safety. At a median follow-up of 7·5 months (IQR 6·5-9·3), overall response and Ctrough met the predefined non-inferiority criteria. An overall response was seen in 108 (41%) of 263 patients in the subcutaneous group and 96 (37%) of 259 in the intravenous group (relative risk 1·11, 95% CI 0·89-1·37). The geometric means ratio for Ctrough was 107·93% (90% CI 95·74-121·67), and the maximum Ctrough was 593 μg/mL (SD 306) in the subcutaneous group and 522 μg/mL (226) in the intravenous group. The most common grade 3 and 4 adverse events were anaemia (34 [13%] of 260 patients evaluable for safety in the subcutaneous group and 36 [14%] of 258 patients in the intravenous group), neutropenia (34 [13%] and 20 [8%]), and thrombocytopenia (36 [14%] and 35 [14%]). Pneumonia was the only serious adverse event in more than 2% of patients (seven [3%] in the subcutaneous group and 11 [4%] in the intravenous group). There was one death resulting from a treatment-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovecii pneumonia [n=1]). INTERPRETATION: Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These data could contribute to the approval of the subcutaneous daratumumab formulation by regulatory bodies. FUNDING: Janssen Research & Development.
Arnie Charbonneau Cancer Institute University of Calgary Calgary AB Canada
Centre Hospitalier Universitaire Bordeaux Pessac France
Clinica São Germano São Paulo Brazil
Department of Haemato Oncology Royal Marsden Hospital London UK
Department of Internal Medicine Falun General Hospital Falun Sweden
Division of Molecular Pathology Institute of Cancer Research London UK
General University Hospital Prague Charles University Prague Czech Republic
Institute of Cancer Molecular and Cellular Biology Salamanca Spain
Institute of Hematology Università Cattolica del Sacro Cuore Rome Italy
Janssen Research and Development Raritan NJ USA
Janssen Research and Development Spring House PA USA
Kiev Bone Marrow Transplantation Center Kiev Ukraine
Levine Cancer Institute Atrium Health Charlotte NC USA
Queen Elizabeth 2 Health Sciences Centre Dalhousie University Halifax NS Canada
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023057
- 003
- CZ-PrNML
- 005
- 20201214125216.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2352-3026(20)30070-3 $2 doi
- 035 __
- $a (PubMed)32213342
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mateos, Maria-Victoria $u Cancer Research Unit, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Institute of Cancer Molecular and Cellular Biology (USAL-CSIC), Centre for Cancer Research (IBMCC), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
- 245 10
- $a Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial / $c MV. Mateos, H. Nahi, W. Legiec, S. Grosicki, V. Vorobyev, I. Spicka, V. Hungria, S. Korenkova, N. Bahlis, M. Flogegard, J. Bladé, P. Moreau, M. Kaiser, S. Iida, J. Laubach, H. Magen, M. Cavo, C. Hulin, D. White, V. De Stefano, PL. Clemens, T. Masterson, K. Lantz, L. O'Rourke, C. Heuck, X. Qin, DA. Parasrampuria, Z. Yuan, S. Xu, M. Qi, SZ. Usmani,
- 520 9_
- $a BACKGROUND: Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. METHODS: In this ongoing, multicentre (147 sites in 18 countries), open-label, non-inferiority, randomised, phase 3 trial, we recruited adult patients (age ≥18 years) if they had confirmed relapsed or refractory multiple myeloma according to International Myeloma Working Group criteria; received at least three previous lines of therapy, including a proteasome inhibitor and immunomodulatory drug, or were double refractory to both a proteasome inhibitor and immunomodulatory drug; and had an Eastern Cooperative Oncology Group performance status score of 2 or lower. Patients were randomly assigned (1:1) by a computer-generated randomisation schedule and balanced using randomly permuted blocks to receive daratumumab subcutaneously (subcutaneous group) or intravenously (intravenous group). Randomisation was stratified on the basis of baseline bodyweight (≤65 kg, 66-85 kg, >85 kg), previous therapy lines (≤four vs >four), and myeloma type (IgG vs non-IgG). Patients received 1800 mg of subcutaneous daratumumab co-formulated with 2000 U/mL recombinant human hyaluronidase PH20 or 16 mg/kg of intravenous daratumumab once weekly (cycles 1-2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter (28-day cycles) until progressive disease or toxicity. The co-primary endpoints were overall response and maximum trough concentration (Ctrough; cycle 3, day 1 pre-dose). The non-inferiority margin for overall response was defined using a 60% retention of the lower bound (20·8%) of the 95% CI of the SIRIUS trial. Efficacy analyses were done by intention-to-treat population. The pharmacokinetic-evaluable population included all patients who received all eight weekly daratumumab doses in cycles 1 and 2 and provided a pre-dose pharmacokinetics blood sample on day 1 of cycle 3. The safety population included all patients who received at least one daratumumab dose. This trial is registered with ClinicalTrials.gov, NCT03277105. FINDINGS: Between Oct 31, 2017, and Dec 27, 2018, 655 patients were screened, of whom 522 were recruited and randomly assigned (subcutaneous group n=263; intravenous group n=259). Three patients in the subcutaneous group and one in the intravenous group did not receive treatment and were not evaluable for safety. At a median follow-up of 7·5 months (IQR 6·5-9·3), overall response and Ctrough met the predefined non-inferiority criteria. An overall response was seen in 108 (41%) of 263 patients in the subcutaneous group and 96 (37%) of 259 in the intravenous group (relative risk 1·11, 95% CI 0·89-1·37). The geometric means ratio for Ctrough was 107·93% (90% CI 95·74-121·67), and the maximum Ctrough was 593 μg/mL (SD 306) in the subcutaneous group and 522 μg/mL (226) in the intravenous group. The most common grade 3 and 4 adverse events were anaemia (34 [13%] of 260 patients evaluable for safety in the subcutaneous group and 36 [14%] of 258 patients in the intravenous group), neutropenia (34 [13%] and 20 [8%]), and thrombocytopenia (36 [14%] and 35 [14%]). Pneumonia was the only serious adverse event in more than 2% of patients (seven [3%] in the subcutaneous group and 11 [4%] in the intravenous group). There was one death resulting from a treatment-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovecii pneumonia [n=1]). INTERPRETATION: Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These data could contribute to the approval of the subcutaneous daratumumab formulation by regulatory bodies. FUNDING: Janssen Research & Development.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000911
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $7 D009101
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Nahi, Hareth $u Unit of Hematology, Department of Medicine, Karolinska University Hospital at Huddinge, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Legiec, Wojciech $u Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
- 700 1_
- $a Grosicki, Sebastian $u Department of Hematology and Cancer Prevention, School of Public Health in Bytom, Medical University of Silesia in Katowice, Katowice, Poland.
- 700 1_
- $a Vorobyev, Vladimir $u S P Botkin City Clinical Hospital, Moscow, Russia.
- 700 1_
- $a Spicka, Ivan $u 1st Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic; General University Hospital in Prague, Charles University, Prague, Czech Republic.
- 700 1_
- $a Hungria, Vania $u Clinica São Germano, São Paulo, Brazil.
- 700 1_
- $a Korenkova, Sibirina $u Kiev Bone Marrow Transplantation Center, Kiev, Ukraine.
- 700 1_
- $a Bahlis, Nizar $u Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
- 700 1_
- $a Flogegard, Max $u Department of Internal Medicine, Falun General Hospital, Falun, Sweden.
- 700 1_
- $a Bladé, Joan $u Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
- 700 1_
- $a Moreau, Philippe $u University Hospital of Nantes, Nantes, France.
- 700 1_
- $a Kaiser, Martin $u Department of Haemato-Oncology, Royal Marsden Hospital, London, UK; Division of Molecular Pathology, Institute of Cancer Research, London, UK.
- 700 1_
- $a Iida, Shinsuke $u Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- 700 1_
- $a Laubach, Jacob $u Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Magen, Hila $u Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv, Israel.
- 700 1_
- $a Cavo, Michele $u Diagnostic and Specialty Medicine Department, Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy.
- 700 1_
- $a Hulin, Cyrille $u Centre Hospitalier Universitaire Bordeaux, Pessac, France.
- 700 1_
- $a White, Darrell $u Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
- 700 1_
- $a De Stefano, Valerio $u Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy; Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.
- 700 1_
- $a Clemens, Pamela L $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a Masterson, Tara $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a Lantz, Kristen $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a O'Rourke, Lisa $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a Heuck, Christoph $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a Qin, Xiang $u Janssen Research & Development, Raritan, NJ, USA.
- 700 1_
- $a Parasrampuria, Dolly A $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a Yuan, Zhilong $u Janssen Research & Development, Raritan, NJ, USA.
- 700 1_
- $a Xu, Steven $u Janssen Research & Development, Spring House, PA, USA; Genmab US, Princeton, NJ, USA.
- 700 1_
- $a Qi, Ming $u Janssen Research & Development, Spring House, PA, USA.
- 700 1_
- $a Usmani, Saad Z $u Levine Cancer Institute-Atrium Health, Charlotte, NC, USA. Electronic address: saad.usmani@atriumhealth.org.
- 773 0_
- $w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 7, č. 5 (2020), s. e370-e380
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32213342 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125215 $b ABA008
- 999 __
- $a ok $b bmc $g 1595376 $s 1113733
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 7 $c 5 $d e370-e380 $e 20200323 $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
- LZP __
- $a Pubmed-20201125
